Synapse - Genitourinary Oncology Service

Results (81)

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal Article

Mantia, C. M.; Jegede, O. A.; Plimack, E. R.; Powles, T.; Motzer, R. J.; Tannir, N. M.; Lee, C. H.; Tomita, Y.; Voss, M. H.; Choueiri, T. K.; more...
Journal for ImmunoTherapy of Cancer (2024)

Fulltext@MSK | Save

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

Journal Article

Lara, P. N.; Villanueva, L.; Ibanez, C.; Erman, M.; Lee, J. L.; Heinrich, D.; Lipatov, O. N.; Gedye, C.; Gokmen, E.; Acevedo, A.; more...
BMC Cancer (2024)

Fulltext@MSK | Save

Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: Diagnostic performance and outcomes using biparametric vs. multiparametric MRI

Journal Article

Woo, S.; Becker, A. S.; Das, J. P.; Ghafoor, S.; Arita, Y.; Benfante, N.; Gangai, N.; Teo, M. Y.; Goh, A. C.; Vargas, H. A.
Cancer Imaging (2023)

Fulltext@MSK | Save

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy

Journal Article

Tvingsholm, S. A.; Frej, M. S.; Rafa, V. M.; Hansen, U. K.; Ormhøj, M.; Tyron, A.; Jensen, A. W. P.; Kadivar, M.; Bentzen, A. K.; Munk, K. K.; more...
Journal for ImmunoTherapy of Cancer (2023)

Fulltext@MSK | Save

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

Journal Article

Autio, K. A.; Higano, C. S.; Nordquist, L.; Appleman, L. J.; Zhang, T.; Zhu, X. H.; Babiker, H.; Vogelzang, N. J.; Prasad, S. M.; Schweizer, M. T.; more...
Journal for ImmunoTherapy of Cancer (2023)

Fulltext@MSK | Save

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

Journal Article

Postel-Vinay, S.; Lam, V. K.; Ros, W.; Bauer, T. M.; Hansen, A. R.; Cho, D. C.; Stephen Hodi, F.; Schellens, J. H. M.; Litton, J. K.; Aspeslagh, S.; more...
Journal for ImmunoTherapy of Cancer (2023)

Fulltext@MSK | Save

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Journal Article

Rudin, C. M.; Pandha, H. S.; Zibelman, M.; Akerley, W. L.; Harrington, K. J.; Day, D.; Hill, A. G.; O'Day, S. J.; Clay, T. D.; Wright, G. M.; more...
Journal for ImmunoTherapy of Cancer (2023)

Fulltext@MSK | Save

Prediction of best response for NSCLC patients receiving immunotherapy by machine learning models

Meeting Abstract

Zhang, Y.; Gupta, S.; Belouali, A.; Lev-Ari, S.; Shah, N.; Krishnamurthy, K.; Serzan, M.; Alaoui, A.; McGarvey, P.; Atkins, M.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors

Meeting Abstract

McGregor, B.; Choueiri, T.; Shah, N.; Bajaj, A.; Chahoud, J.; O'Neil, B.; Michalski, J.; Garmezy, B.; Jin, L.; Aziz, U.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma

Meeting Abstract

Aggen, D.; McKean, M.; Lakhani, N.; Bashir, B.; Hoffman-Censits, J.; Alhalabi, O.; Guancial, E.; Bowman, I.; Tan, A.; Lingaraj, T.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save